1. Home
  2. TKNO vs DBVT Comparison

TKNO vs DBVT Comparison

Compare TKNO & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TKNO
  • DBVT
  • Stock Information
  • Founded
  • TKNO 1996
  • DBVT 2002
  • Country
  • TKNO United States
  • DBVT France
  • Employees
  • TKNO N/A
  • DBVT N/A
  • Industry
  • TKNO Medicinal Chemicals and Botanical Products
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TKNO Health Care
  • DBVT Health Care
  • Exchange
  • TKNO Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • TKNO 256.9M
  • DBVT 260.5M
  • IPO Year
  • TKNO 2021
  • DBVT N/A
  • Fundamental
  • Price
  • TKNO $4.72
  • DBVT $9.73
  • Analyst Decision
  • TKNO
  • DBVT Buy
  • Analyst Count
  • TKNO 0
  • DBVT 4
  • Target Price
  • TKNO N/A
  • DBVT $14.81
  • AVG Volume (30 Days)
  • TKNO 153.5K
  • DBVT 33.2K
  • Earning Date
  • TKNO 11-06-2025
  • DBVT 11-05-2025
  • Dividend Yield
  • TKNO N/A
  • DBVT N/A
  • EPS Growth
  • TKNO N/A
  • DBVT N/A
  • EPS
  • TKNO N/A
  • DBVT N/A
  • Revenue
  • TKNO $38,923,000.00
  • DBVT $3,800,000.00
  • Revenue This Year
  • TKNO $9.52
  • DBVT $1,743.46
  • Revenue Next Year
  • TKNO $15.20
  • DBVT $1,045.66
  • P/E Ratio
  • TKNO N/A
  • DBVT N/A
  • Revenue Growth
  • TKNO 11.40
  • DBVT N/A
  • 52 Week Low
  • TKNO $3.94
  • DBVT $2.21
  • 52 Week High
  • TKNO $10.37
  • DBVT $12.78
  • Technical
  • Relative Strength Index (RSI)
  • TKNO 56.82
  • DBVT 52.33
  • Support Level
  • TKNO $4.24
  • DBVT $9.50
  • Resistance Level
  • TKNO $4.72
  • DBVT $10.50
  • Average True Range (ATR)
  • TKNO 0.30
  • DBVT 0.43
  • MACD
  • TKNO 0.05
  • DBVT 0.06
  • Stochastic Oscillator
  • TKNO 95.61
  • DBVT 57.22

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: